GLP-1s for PCOS weight loss: what the evidence actually supports

What did @unapologetic.bits actually say?

The creator, who describes herself as a weight loss clinic owner with PCOS, filmed herself self-injecting what she called "17 units of tear septide" (tirzepatide) while narrating injection technique for her audience. She covered three injection sites: the abdomen ("two finger widths away from the umbilicus"), the outer thigh, and the back of the arm. She also described cleaning the skin with "an alcohol slob" and holding the medication in for "about 5 to 10 seconds" before removing the needle. The framing is personal and vulnerable, but the content is functionally instructional. That matters, because a lot of people watching this will take it as clinical guidance, regardless of her intent.

She identifies herself as a healthcare provider, which adds a layer of implied authority. That's worth holding onto as we look at what she got right and what she got wrong.

Does the science back this up?

On injection site selection, she is broadly correct. The core guidance checks out. The abdomen, thigh, and upper arm are all FDA-approved injection sites for tirzepatide (Zepbound/Mounjaro), and the two-finger-width clearance from the navel is standard clinical instruction.

The "5 to 10 second" hold time she mentions is a real technique, though it applies more to older pen devices designed to ensure full dose delivery. Eli Lilly's official prescribing information for Mounjaro instructs users to hold the pen in place until the gray plunger is visible, which typically takes around 10 seconds. The principle is sound, even if the reason behind it isn't explained here.

Alcohol swabbing before subcutaneous injection is standard practice, per CDC injection safety guidelines. The "very, very small needle" comment is accurate, tirzepatide pens use a 4mm or 5mm 29-gauge needle, which most patients tolerate well. A 2023 real-world adherence study by Frias et al. in Diabetes Care noted that needle anxiety is a documented barrier to GLP-1 initiation, so normalizing needle size is genuinely useful.

What did they get wrong (or right)?

The most significant issue here is the dose. She says she administered "17 units of tear septide." Tirzepatide is not dosed in units. It is dosed in milligrams, delivered via a fixed-dose pen. Mounjaro and Zepbound come in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg auto-injectors. There is no user-adjustable unit measurement in the FDA-approved product. If she is drawing from a vial and dosing in units, she may be using a compounded version, which is a separate product with different concentration, formulation, and regulatory status. Compounded tirzepatide is not equivalent to FDA-approved tirzepatide. The FDA has stated explicitly that compounded versions have not been shown to be safe or effective in the same way. Conflating the two in a public instructional video is a real problem.

The mispronunciation as "tear septide" is minor and probably just a slip. The bigger issue is presenting a dose format that does not match the approved product without any clarification for viewers who may be managing their own prescriptions.

What she got right: injection site rotation guidance, needle size framing, and the general "quick jab" technique for subcutaneous delivery are all reasonable and consistent with clinical instruction.

What should you actually know?

If you are starting tirzepatide, here is what actually matters. First, the dose format. FDA-approved tirzepatide comes in pre-filled auto-injectors measured in milligrams, not units. If your provider or pharmacy is giving you a syringe and telling you to draw units, you are using a compounded product. That is not automatically wrong, but you need to know the difference, because concentration varies by compounder and dosing errors are a documented risk.

Second, injection site rotation matters beyond what was shown here. Repeatedly injecting the same spot can cause lipohypertrophy, a buildup of fatty tissue that slows drug absorption. The American Diabetes Association recommends systematic rotation within and across sites.

Third, tirzepatide is a dual GIP and GLP-1 receptor agonist. It is approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). It is not a general wellness supplement, and starting it without a clinical evaluation for contraindications, including a personal or family history of medullary thyroid carcinoma or MEN2, is genuinely dangerous. A TikTok video, even from a clinic owner, is not a substitute for that evaluation.

Bottom line

This video is more accurate than most GLP-1 content on TikTok. The injection mechanics are largely correct. But the dose terminology is a real red flag that suggests compounded tirzepatide use without disclosure, and that distinction matters for anyone trying to follow along at home. Give credit where it is due, but do not let the personal vulnerability framing substitute for clinical precision.